Volume 28, Number 7—July 2022
Research Letter
Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
Toshihiro Sato, Shinjiro Kodama, Keizo Kaneko, Junta Imai, and Hideki Katagiri
Table
Laboratory test results for a patient who had type 1 diabetes mellitus associated with nivolumab after a second SARS-CoV-2 vaccination, Japan*
| Laboratory test | Value |
|---|---|
| Venous blood gas analysis | |
| pH | 7.36 |
| pCO2, mm Hg | 41.1 |
| Bicarbonate, mmol/L | 22.6 |
| Anion gap, mmol/L |
10.0 |
| Biochemical | |
| Creatinine, mg/dL | 0.84 |
| Glomerular filtration rate, mL/min/1.73 m2 | 79.0 |
| Amylase, U/L | 59.0 |
| Lipase, U/L |
26.0 |
| Diabetes-related tests | |
| Plasma glucose, mg/dL | 665 |
| HbA1c, % | 8.0 |
| Acetoacetate, μmol/L | 1,936 |
| 3-hydroxybutyric acid, μmol/L | 2,813 |
| Fasting CPR, ng/mL | 0.13 |
| 24-h CPR, μg/day† | 5.74/3.82 |
| GAD antibody, U/mL | <5.0 |
| IA-2 antibody, U/mL | <0.4 |
| ZnT8 antibody, U/mL |
<10 |
| Glucagon load test | |
| Fasting CPR, ng/mL | 0.09 |
| After 6 min CPR, ng/mL | 0.12 |
| Delta CPR, ng/mL |
0.03 |
| DNA typing | |
| HLA-DRB1*11:01-DQB1*03:01:01 | NA |
| HLA-DRB1*13:02:01-DQB1*06:04:01 | NA |
*CPR, C-peptide immunoreactivity; GAD, glutamic acid decarboxylase; HbA1c, glycated hemoglobin; HLA, human leukocyte antigen; IA-2, insulinoma-associated antigen 2; NA, not applicable; ZnT8, zinc transporter 8. †The 24-h CPR was measured twice for this patient because values can fluctuate greatly for patients who have diabetes.
Page created: April 19, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.